BBIO · Categories · Form 4
BBIO - SEC Form 4 insider transactions
BridgeBio Pharma Inc. (BBIO) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for BBIO
- Director Ellis Andrea exercised 17,167 shares at a strike of $16.75 and sold $1,442,028 worth of shares (17,167 units at $84.00) as part of a pre-agreed trading plan (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Cook Jennifer E. sold $13,156,008 worth of shares (148,589 units at $88.54) as part of a pre-agreed trading plan and exercised 148,589 shares at a strike of $24.96 (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Valantine Hannah was granted 3,990 shares, exercised 2,808 shares at a strike of $41.73 and sold $341,524 worth of shares (5,004 units at $68.25) as part of a pre-agreed trading plan, increasing direct ownership by 24% to 9,259 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Cook Jennifer E. was granted 3,990 shares, sold $2,752,270 worth of shares (39,363 units at $69.92) as part of a pre-agreed trading plan and exercised 37,167 shares at a strike of $12.28, increasing direct ownership by 27% to 8,383 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Lo Andrew was granted 3,990 shares, increasing direct ownership by 28% to 18,079 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Homcy Charles J was granted 3,990 shares, increasing direct ownership by 0.44% to 919,876 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Daniels Ronald J was granted 3,990 shares, increasing direct ownership by 23% to 20,981 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Aguiar Eric was granted 3,990 shares, increasing direct ownership by 61% to 10,579 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Ellis Andrea was granted 3,990 shares, increasing direct ownership by 21% to 22,579 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Momtazee James C was granted 3,990 shares, increasing direct ownership by 26% to 19,070 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Hassan Fred was granted 3,990 shares, increasing direct ownership by 15% to 29,879 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Mccormick Frank was granted 3,990 shares, increasing direct ownership by 61% to 10,579 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Satvat Ali J. was granted 3,990 shares, increasing direct ownership by 2% to 169,983 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Dachille Douglas A. was granted 3,990 shares, increasing direct ownership by 61% to 10,579 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Homcy Charles J covered exercise/tax liability with 788 shares, decreasing direct ownership by 0.09% to 915,886 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Cook Jennifer E. exercised 83,088 shares at a strike of $10.16 and sold $6,012,157 worth of shares (90,240 units at $66.62) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,589 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $5,413,289 worth of shares (80,000 units at $67.67) as part of a pre-agreed trading plan (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $1,812,522 worth of shares (26,103 units at $69.44) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 243,327 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas covered exercise/tax liability with 22,781 shares and sold $888,419 worth of shares (13,651 units at $65.08) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 359,194 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil converted options into 71,215 shares and covered exercise/tax liability with 36,236 shares, increasing direct ownership by 15% to 269,430 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 4,714 shares, decreasing direct ownership by 4% to 129,401 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Scott Randal W. exercised 10,000 shares at a strike of $16.75 and sold $671,456 worth of shares (10,000 units at $67.15) as part of a pre-agreed trading plan (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $5,392,243 worth of shares (80,000 units at $67.40) as part of a pre-agreed trading plan (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel sold $143,160 worth of shares (2,000 units at $71.58) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 134,115 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- SEC Form 4 filed by Kumar Neil4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- SEC Form 4 filed by Trimarchi Thomas4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- SEC Form 4 filed by Apuli Maricel4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- SEC Form 4 filed by Kumar Neil4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $5,501,068 worth of shares (80,000 units at $68.76) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Valantine Hannah exercised 8,671 shares at a strike of $27.36 and sold $624,312 worth of shares (8,671 units at $72.00) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Ellis Andrea exercised 64,921 shares at a strike of $8.45 and sold $4,211,302 worth of shares (64,921 units at $64.87) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Valantine Hannah exercised 25,484 shares at a strike of $48.45 and sold $1,717,781 worth of shares (25,484 units at $67.41) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel sold $132,000 worth of shares (2,000 units at $66.00), decreasing direct ownership by 2% to 121,945 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $2,002,717 worth of shares (28,053 units at $71.39), decreasing direct ownership by 11% to 234,451 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil converted options into 64,698 shares and covered exercise/tax liability with 30,970 shares, increasing direct ownership by 15% to 262,504 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 4,349 shares and sold $37,898 worth of shares (510 units at $74.31), decreasing direct ownership by 4% to 123,945 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas sold $1,016,147 worth of shares (13,600 units at $74.72) and covered exercise/tax liability with 18,819 shares, decreasing direct ownership by 9% to 336,585 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Scott Randal W. exercised 10,000 shares at a strike of $16.75 and sold $754,557 worth of shares (10,000 units at $75.46) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $5,748,666 worth of shares (80,000 units at $71.86) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $6,043,168 worth of shares (80,000 units at $75.54) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil converted options into 60,975 shares, covered exercise/tax liability with 30,964 shares and sold $2,239,902 worth of shares (30,011 units at $74.64) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas covered exercise/tax liability with 13,826 shares, decreasing direct ownership by 4% to 369,004 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 2,003 shares, decreasing direct ownership by 2% to 128,294 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel sold $148,520 worth of shares (2,000 units at $74.26), decreasing direct ownership by 2% to 130,297 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $5,908,476 worth of shares (80,000 units at $73.86) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $1,722,224 worth of shares (26,156 units at $65.84), decreasing direct ownership by 10% to 228,776 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Lo Andrew sold $6,319,662 worth of shares (95,599 units at $66.11), decreasing direct ownership by 74% to 14,089 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Scott Randal W. exercised 10,000 shares at a strike of $16.75 and sold $666,465 worth of shares (10,000 units at $66.65) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil converted options into 64,697 shares and covered exercise/tax liability with 32,855 shares, increasing direct ownership by 14% to 254,932 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas covered exercise/tax liability with 21,317 shares and sold $1,125,404 worth of shares (16,934 units at $66.46), decreasing direct ownership by 9% to 382,830 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 4,781 shares, decreasing direct ownership by 3% to 132,297 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Valantine Hannah exercised 25,484 shares at a strike of $48.45 and sold $1,683,728 worth of shares (25,484 units at $66.07) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $4,983,111 worth of shares (80,000 units at $62.29) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Daniels Ronald J exercised 61,031 shares at a strike of $34.65 and sold $3,888,999 worth of shares (61,031 units at $63.72) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Mccormick Frank sold $13,206,528 worth of shares (198,359 units at $66.58) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Mccormick Frank sold $106,665 worth of shares (1,641 units at $65.00) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $4,383,442 worth of shares (80,000 units at $54.79) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Director Mccormick Frank sold $3,933,544 worth of shares (74,000 units at $53.16) and exercised 74,000 shares at a strike of $11.92 (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- Chief Executive Officer Kumar Neil sold $4,175,835 worth of shares (80,000 units at $52.20) (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
- President and CFO Trimarchi Thomas sold $2,090,081 worth of shares (42,237 units at $49.48), decreasing direct ownership by 9% to 421,081 units (SEC Form 4)4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)